This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schneider, M. D. Articles by Schwartz, R. J. Search for Related Content PubMed PubMed Citation Articles by Schneider, M. D. Articles by Schwartz, R. J. Related Collections Gene expression Genomics Heart failure - basic studies

(Circulation. 2000;102:3026.)
© 2000 American Heart Association, Inc.

Editorial

Chips Ahoy

Gene Expression in Failing Hearts Surveyed by High-Density Microarrays

Michael D. Schneider, MD; Robert J. Schwartz, MD

From the Center for Cardiovascular Development (M.D.S., R.J.S.), Departments of Medicine (M.D.S.), Molecular and Cellular Biology (M.D.S, R.J.S.), and Molecular Physiology and Biophysics (M.D.S, R.J.S), Baylor College of Medicine, Houston, Tex.

Correspondence to Michael D. Schneider, MD, Molecular Cardiology Unit, Baylor College of Medicine, One Baylor Plaza, Room 506C, Houston, TX 77030. E-mail michaels@bcm.tmc.edu

Key Words: Editorials • genetics • heart failure

Organ-level heart failure can result, most obviously, from the death of cardiac myocytes; such death can occur either acutely (with infarction) or more sporadically (in chronic disease). Both types of death can involve a "cell suicide" pathway known as apoptosis.¹ Another key factor for cardiac dysfunction is myocardial fibrosis, which can be, in part, a direct consequence of angiotensin II levels; therefore, a possible benefit of therapy with angiotensin-converting enzyme inhibitors is an improvement in fibrosis. A third generic mechanism for defects in macroscopic or clinically evident cardiac performance arises from changes in the intrinsic mechanical properties of individual cardiac muscle cells.² This phenomenon is understood to occur, in part, through changes in the expression of cardiac genes, both subtle and overt, which are collectively referred to as the hypertrophic gene "program."³ Reprogramming cardiac gene expression encompasses, among its other features, alterations in (1) contractile proteins of the sarcomere, (2) regulators of calcium handling and other aspects of ion transport, and (3) secreted growth factors and cytokines. Therefore, in pursuit of potential targets for therapy, 2 important aspects of contemporary heart failure research are to discover the signaling pathways that confer adverse responses^{3 4} and to establish a much more comprehensive understanding of the end-organ changes that actually occur.

In the current issue of Circulation, Yang et al⁵ performed a mammoth screen for altered gene expression in heart failure using a newly developed technology, high-density DNA microarrays.⁶ Although conceptually simple, these assays are a technical tour de force (Figure). . . . [Full Text of this Article]

This article has been cited by other articles:

				J. K. F. Hon and M. H. Yacoub Bridge to recovery with the use of left ventricular assist device and clenbuterol Ann. Thorac. Surg., June 1, 2003; 75(90060): S36 - 41. [Abstract] [Full Text] [PDF]

				I. M.C. Dixon Help from within: cardioprotective properties of hepatocyte growth factor Cardiovasc Res, July 1, 2001; 51(1): 4 - 6. [Full Text] [PDF]